Yong Chan Kim

Yong Chan Kim is a prominent biotechnology executive currently serving as Chief Scientific Officer at Baudax Bio since August 2023, focusing on the development of clinical-grade TCR-Treg cell production for Hemophilia A. Prior to this role, Yong Chan Kim held the position of Chief Executive Officer and Chief Scientific Officer at TeraImmune, Inc. from August 2019 to July 2023, where significant contributions were made to the early-stage development of immune cell therapies. As Vice President of Research at TeraImmune LLC from April 2018 to July 2019, Yong Chan Kim led the transition of TCR-Treg therapy from academic research to practical applications. Yong Chan Kim's academic background includes research positions at the Uniformed Services University and NIAID, NIH, where various projects focused on TCR-Treg therapy were conducted. Yong Chan Kim earned a Ph.D. in Biochemistry from Chungnam National University in 2006.